Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 14/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 2/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087502 | 0.81 | AVPR1B (0.62) | AVPR1BCYP3A4HTR7 | |
| SCHEMBL4077589 | 0.79 | AVPR1B (0.90) | AVPR1BCYP3A4 | |
| SCHEMBL4085615 | 0.79 | AVPR1B (0.59) | AVPR1BCYP3A4 | |
| SCHEMBL4080681 | 0.73 | AVPR1B (0.88) | AVPR1BCYP3A4 | |
| SCHEMBL2885086 | 0.73 | AVPR1B (0.51) | AVPR1BTNF | |
| SCHEMBL4085601 | 0.72 | AVPR1B (1.00) | AVPR1BCYP3A4 | |
| SCHEMBL4081698 | 0.70 | AVPR1B (0.92) | AVPR1BCYP3A4 | |
| SCHEMBL4077879 | 0.70 | AVPR1B (0.92) | AVPR1BCYP3A4 | |
| SCHEMBL4087661 | 0.69 | AVPR1B (1.00) | AVPR1BCYP3A4 | |
| SCHEMBL2889009 | 0.69 | AVPR1B (0.83) | AVPR1BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431567-B2 | Substituted oxindole derivatives and their use as vasopressin and/or oxytocin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2013-04-30 | — | — | US | disclosed |
| US-20090318406-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318406-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | OXTR, AVPR2, AVPR1B | AVPR1B 3/4885CYP3A4 3668/4885HTR7 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.